Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Shares Outstanding (Diluted Average): 2021-2024

Historic Shares Outstanding (Diluted Average) for Autolus Therapeutics (AUTL) over the last 3 years, with Dec 2024 value amounting to $255.2 million.

  • Autolus Therapeutics' Shares Outstanding (Diluted Average) rose 0.02% to $266.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.1 million, marking a year-over-year increase of 0.02%. This contributed to the annual value of $255.2 million for FY2024, which is 46.69% up from last year.
  • Per Autolus Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $255.2 million for FY2024, which was up 46.69% from $173.9 million recorded in FY2023.
  • Autolus Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $255.2 million during FY2024, with a 5-year trough of $99.2 million in FY2021.
  • For the 2-year period, Autolus Therapeutics' Shares Outstanding (Diluted Average) averaged around $214.6 million, with its median value being $214.6 million (2023).
  • Data for Autolus Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY surged of 46.69% (in 2024) over the last 5 years.
  • Autolus Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $99.2 million in 2021, then reached $173.9 million in 2023, then skyrocketed by 46.69% to $255.2 million in 2024.